Hormonal
Once-weekly subcutaneous semaglutide 2.4 mg produces significant weight loss in adults with overweight or obesity, with efficacy largely independent of baseline characteristics such as age, race, BMI, and glycemic status, though females and those with lower baseline body weight experience greater magnitude of loss.
If you have obesity or overweight, once-weekly semaglutide (2.4 mg) is a highly effective treatment for weight loss, regardless of your age, race, or starting weight. However, be aware that women and those with a lower starting body weight tend to lose more weight than men or those with a higher starting body weight. This treatment is used alongside lifestyle changes.
In STEP 1, weight loss with once-weekly s.c. semaglutide 2.4 mg was seen in all subgroups evaluated, and was generally not influenced by baseline characteristics. The exception was sex and baseline body weight; female sex and a low baseline body weight were associated with a greater response to semaglutide.
Why this rating
Based on a randomized, double-blind, placebo-controlled phase 3 trial (STEP 1) with 1,961 participants.
Source
Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)
Swaroop H Suresh et al. · Indian Journal of Endocrinology and Metabolism · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →